Tag: Evoke spinal cord stimulator system
Saluda receives US FDA approval for MRI labelling of Evoke spinal...
Saluda Medical has announced that the US Food and Drug Administration (FDA) has approved magnetic resonance imaging (MRI) conditional labelling for its Evoke system,...
Saluda announces sustained, long-term pain relief results with closed-loop SCS in...
Saluda Medical today announced long-term results from its double-blind, Level 1 EVOKE trial, which have been published in JAMA Neurology and demonstrate superior, sustained pain...
Saluda Medical results of US Evoke pivotal study through 12 months...
Saluda Medical has announced The Lancet Neurology journal published results from the US pivotal study demonstrating its Evoke ECAP-controlled, closed-loop spinal cord stimulation (SCS)...
Saluda Medical announces European commercial launch of Evoke, the ECAP-controlled, closed-loop...
Saluda Medical has announced the award of CE mark and the European commercial launch of the Evoke ECAP-controlled, closed-loop spinal cord stimulation (SCS) system...
The clinical utility of evoked compound action potentials is echoed by...
New data from both the Evoke and Avalon studies reiterate the importance of objective neurophysiological measures and clinically meaningful outcomes. These studies evaluated the...
Saluda Medical raises US$75 million equity financing from Boston Scientific and...
Following the announcement of the debt financing with Medtronic, Saluda Medical has announced that it has secured US$75 million in equity financing from Boston...
Saluda Medical secures debt financing from Medtronic
Saluda Medical has announced that it has secured a four-year term loan agreement with Medtronic, to fund continued development of its Evoke ECAP-controlled, closed-loop...
Saluda Medical secures US$40 million in series D financing
Saluda Medical, a medical device company developing a platform of closed-loop neuromodulation technologies based on neural response to stimulation, has secured US$40 million in...
